9 Meters Biopharma, Inc.

9 Meters Biopharma, Inc. (NASDAQ: NMTR) is a clinical-stage company focused on treating rare or debilitating digestive diseases. Its primary products are vurolenatide, an innovative Phase 2 GLP-1 agonist for short bowel syndrome (SBS), and larazotide, a regulator for non-responsive celiac disease.

Key Highlights

• The company is yet to generate any revenues.
• Its net loss for Q3FY21 (ended September 30, 2021) increased to USD 13.5 million from USD 8.3 million reported in Q3FY20.
• On November 10, 2021, NMTR signed a collaboration agreement with Gustave Roussy, a leading cancer center located in Villejuif, France. Gustave Roussy will use NMTR's small molecule tight junction microbiome modulator NM-102 for preventing gut microbial metabolites and antigens from trafficking into the systemic circulation.
• The stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, and its RSI Index is at 29.16.
• It is currently trading close to the lower end of its 52-week range of USD 0.70 to USD 2.26.
• NMTR's stock price corrected 40.98% and 48.83% in the past six and nine months, respectively.

Technical Price Chart (as of December 13, 2021). Analysis by Kalkine

Conclusion: Considering the company's loss-making status, lacklustre fundamentals, and other technical indicators, we recommend an "Avoid" rating on the stock at the current price of USD 0.8853, down 2.61%, as of December 13, 2021, at 12:58 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer

References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited.

This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. Kalkine Limited is authorised and regulated by the Financial Conduct Authority under reference number 579414.

The article has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation.

Kalkine does not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not intend to exclude any liability which it is not permitted to exclude under applicable law or regulation. Kalkine’s non-personalised advice does not in any way endorse or recommend individuals, investment products or services for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional authorised financial planner and adviser. You should be aware that the value of any investment and the income from it can go down as well as up and you may not get back the amount invested.

Kalkine Media Limited, an affiliate of Kalkine Limited, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.